BioCentury
ARTICLE | Finance

Ebb & Flow

June 29, 2009 7:00 AM UTC

Novo's crossover ambitions

Novo A/S has tripled its commitment to life sciences venture investment from roughly $100 million to $300 million annually. Last week, Novo unveiled its evergreen Novo Growth Equity fund, which will invest $200 million annually in late stage private and small cap public life sciences companies...